COVID-19 mRNA vaccine effectiveness (second and first booster dose) against hospitalisation and death during Omicron BA.5 circulation: cohort study based on electronic health records, Portugal, May to July 2022

被引：562
|
作者：
Kislaya, Irina [1 ,2 ]
Machado, Ausenda [1 ,2 ]
Magalhaes, Sarah
Rodrigues, Ana Paula
Franco, Rafael
Leitek, Pedro Pinto [3 ,4 ]
Dias, Carlos Matias [1 ,2 ]
Nunes, Baltazar [1 ,2 ]
机构：
[1] Inst Nacl Sailde Doutor Ricardo Jorge, Dept Epidemiol, Lisbon, Portugal
[2] Univ NOVA Lisboa, Ctr Invest Saude Publ, Escola Nacl Saude Publ, Lisbon, Portugal
[3] Serv Partilhados Minist Saude, Lisbon, Portugal
[4] Direcao Servi Informacao & Analise, Direcao Geral Saude, Lisbon, Portugal
来源：
EUROSURVEILLANCE | 2022年 / 27卷 / 37期
关键词：
D O I：
10.2807/1560-7917.ES.2022.27.37.2200697
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
We measured vaccine effectiveness (VE) against COVID-19-related severe outcomes in elderly people in Portugal between May and July 2022. In 2 80 year -olds, the second booster dose VE was 81% (95% CI: 75-85) and 82% (95% CI: 77-85), respectively, against COVID-19-related hospitalisation and death. The first booster dose VE was 63% (95% CI: 55-70) in 2 80 year -olds and 74% (95% CI: 66-80) in 60-79 year-olds against hospitalisation, and 63% (95% CI: 57-69) and 65% (95% CI: 54-74) against death.
引用
收藏
页数：6
相关论文
共 41 条
  • [31] mRNA vaccine effectiveness against COVID-19-related hospitalisations and deaths in older adults: a cohort study based on data linkage of national health registries in Portugal, February to August 2021
    Nunes, Baltazar
    Rodriguesl, Ana Paula
    Kislaya, Irina
    Cruz, Camila
    Peralta-Santos, Andre
    Lima, Joao
    Leitek, Pedro Pinto
    Sequeira, Duarte
    Dias, Carlos Matias
    Machado, Ausenda
    EUROSURVEILLANCE, 2021, 26 (38)
  • [32] Effectiveness of a COVID-19 Additional Primary or Booster Vaccine Dose in Preventing SARS-CoV-2 Infection Among Nursing Home Residents During Widespread Circulation of the Omicron Variant - United States, February 14-March 27, 2022
    Prasad, Namrata
    Derado, Gordana
    Nanduri, Srinivas Acharya
    Reses, Hannah E.
    Dubendris, Heather
    Wong, Emily
    Soe, Minn Minn
    Li, Qunna
    Dollard, Philip
    Bagchi, Suparna
    Edwards, Jonathan
    Shang, Nong
    Budnitz, Dan
    Bell, Jeneita
    Verani, Jennifer R.
    Benin, Andrea
    Link-Gelles, Ruth
    Jernigan, John
    Pilishvili, Tamara
    MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT, 2022, 71 (18): : 633 - 637
  • [33] Estimating vaccine effectiveness against COVID-19 using cause-specific sick leave as an indicator: a nationwide population-based cohort study, Norway, July 2021-December 2022
    Meijerink, Hinta
    Veneti, Lamprini
    Kristoffersen, Anja Brathen
    Danielsen, Anders Skyrud
    Stecher, Melanie
    Starrfelt, Jostein
    BMC PUBLIC HEALTH, 2024, 24 (01)
  • [34] Relative effectiveness of monovalent and bivalent mRNA boosters in preventing severe COVID-19 due to omicron BA.5 infection up to 4 months post-administration in people aged 60 years or older in Italy: a retrospective matched cohort study
    Mateo-Urdiales, Alberto
    Sacco, Chiara
    Fotakis, Emmanouil Alexandros
    Del Manso, Martina
    Bella, Antonino
    Riccardo, Flavia
    Bressi, Marco
    Rota, Maria Cristina
    Petrone, Daniele
    Siddu, Andrea
    Fedele, Giorgio
    Stefanelli, Paola
    Palamara, Anna Teresa
    Brusaferro, Silvio
    Rezza, Giovanni
    Pezzotti, Patrizio
    Fabiani, Massimo
    LANCET INFECTIOUS DISEASES, 2023, 23 (12): : 1349 - 1359
  • [35] Waning effectiveness of BNT162b2 and ChAdOx1 covid-19 vaccines over six months since second dose: OpenSAFELY cohort study using linked electronic health records
    Horne, Elsie M. F.
    Hulme, William J.
    Keogh, Ruth H.
    Palmer, Tom M.
    Williamson, Elizabeth J.
    Parker, Edward P. K.
    Green, Amelia
    Walker, Venexia
    Walker, Alex J.
    Curtis, Helen
    Fisher, Louis
    MacKenna, Brian
    Croker, Richard
    Hopcroft, Lisa
    Park, Robin Y.
    Massey, Jon
    Morley, Jessica
    Mehrkar, Amir
    Bacon, Sebastian
    Evans, David
    Inglesby, Peter
    Morton, Caroline E.
    Hickman, George
    Davy, Simon
    Ward, Tom
    Dillingham, Iain
    Goldacre, Ben
    Hernan, Miguel A.
    Sterne, Jonathan A. C.
    BMJ-BRITISH MEDICAL JOURNAL, 2022, 378
  • [36] Comparative complete scheme and booster effectiveness of COVID-19 vaccines in preventing SARS-CoV-2 infections with SARS-CoV-2 Omicron (BA.1) and Delta (B.1.617.2) variants: A case-case study based on electronic health records
    Kislaya, Irina
    Peralta-Santos, Andre
    Borges, Vitor
    Vieira, Luis
    Sousa, Carlos
    Ferreira, Bibiana
    Pelerito, Ana
    Gomes, Joao Paulo
    Leite, Pedro Pinto
    Nunes, Baltazar
    INFLUENZA AND OTHER RESPIRATORY VIRUSES, 2023, 17 (03)
  • [37] Relative effectiveness of bivalent Original/Omicron BA.4-5 mRNA vaccine in preventing severe COVID-19 in persons 60 years and above during SARS-CoV-2 Omicron XBB.1.5 and other XBB sublineages circulation, Italy, April to June 2023
    Fabiani, Massimo
    Mateo-Urdiales, Alberto
    Sacco, Chiara
    Cristina, Maria
    Fotakis, Emmanouil Alexandros
    Petrone, Daniele
    Del Manso, Martina
    Siddu, Andrea
    Stefanelli, Paola
    Bella, Antonino
    Riccardo, Flavia
    Rezza, Giovanni
    Palamara, Anna Teresa
    Brusaferro, Silvio
    Pezzotti, Patrizio
    EUROSURVEILLANCE, 2023, 28 (32) : 2 - 8
  • [38] Covid-19 and influenza vaccine effectiveness against associated hospital admission and death among individuals over 65 years in Norway: A population-based cohort study, 3 October 2022 to 20 June 2023
    Seppala, Elina
    Dahl, Jesper
    Veneti, Lamprini
    Rydland, Kjersti Margrethe
    Kluwer, Birgitte
    Rohringer, Andreas
    Meijerink, Hinta
    VACCINE, 2024, 42 (03) : 620 - 628
  • [39] Effectiveness of Monovalent mRNA Vaccines Against COVID-19-Associated Hospitalization Among Immunocompetent Adults During BA.1/BA.2 and BA.4/BA.5 Predominant Periods of SARS-CoV-2 Omicron Variant in the United States - IVY Network, 18 States, December 26, 2021-August 31, 2022
    Surie, Diya
    Bonnell, Levi
    Adams, Katherine
    Gaglani, Manjusha
    Ginde, Adit A.
    Douin, David J.
    Talbot, H. Keipp
    Casey, Jonathan D.
    Mohr, Nicholas M.
    Zepeski, Anne
    McNeal, Tresa
    Ghamande, Shekhar
    Gibbs, Kevin W.
    Files, D. Clark
    Hager, David N.
    Shehu, Arber
    Frosch, Anne P.
    Erickson, Heidi L.
    Gong, Michelle N.
    Mohamed, Amira
    Johnson, Nicholas J.
    Srinivasan, Vasisht
    Steingrub, Jay S.
    Peltan, Ithan D.
    Brown, Samuel M.
    Martin, Emily T.
    Khan, Akram
    Bender, William S.
    Duggal, Abhijit
    Wilson, Jennifer G.
    Qadir, Nida
    Chang, Steven Y.
    Mallow, Christopher
    Rivas, Carolina
    Kwon, Jennie H.
    Exline, Matthew C.
    Lauring, Adam S.
    Shapiro, Nathan I.
    Halasa, Natasha
    Chappell, James D.
    Grijalva, Carlos G.
    Rice, Todd W.
    Stubblefield, William B.
    Baughman, Adrienne
    Womack, Kelsey N.
    Hart, Kimberly W.
    Swan, Sydney A.
    Zhu, Yuwei
    DeCuir, Jennifer
    Tenforde, Mark W.
    MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT, 2022, 71 (42): : 1327 - 1334
  • [40] Relative vaccine effectiveness of the booster dose of COVID-19 vaccine for preventing death in individuals with a primary regimen based on the BBIBP-CorV, ChAdOx1-S, or BNT162b2 vaccines during the Omicron wave in Peru: A nested case-control study using national population data
    Silva-Valencia, Javier
    Soto-Becerra, Percy
    Escobar-Agreda, Stefan
    Fernandez-Navarro, Manuel
    Elorreaga, Oliver A.
    Mayta-Tristan, Percy
    Mezones-Holguin, Edward
    Solari, Lely
    VACCINE, 2022, 40 (45) : 6512 - 6519
12345